This article discusses unapproved drug substances, research peptides, or compounded medications, not dietary supplements. These substances are not FDA-approved for wellness use, and FDA does not verify compounded drugs for safety, effectiveness, or quality before marketing. Do not inject, purchase, compound, or substitute unapproved peptides based on this content; consult a licensed clinician for personal medical questions.

Peptide Safety Research

TB-500 FDA status after the July 2026 advisory vote

On July 23, 2026, the Pharmacy Compounding Advisory Committee recommended that FDA consider adding TB-500 free base and TB-500 acetate to the Section 503A Bulks List. Across the July 23-24 hearing, the committee issued favorable recommendations for six peptide groups—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—and recommended against emideltide/DSIP. Those non-binding recommendations ran contrary to FDA staff's pre-meeting position against every reviewed form, but they did not approve TB-500 or immediately authorize compounding or retail sale. As of July 26, FDA had not issued final agency action. TB-500 remains an unapproved drug, not a supplement or over-the-counter recovery product. FDA staff cited missing direct human exposure evidence for the LKKTETQ fragment and concerns involving immunogenicity, aggregation, peptide-related impurities, and API characterization. WADA's separate athlete prohibition also remains in place.

Written by Editorial Team·Medically reviewed by Angelique Nicole R. Villegas, RND·Updated July 26, 2026

This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Quick answer

PCAC recommended TB-500 for possible inclusion on the 503A Bulks List, but the vote was non-binding. TB-500 is still not FDA-approved for recovery, injury repair, bodybuilding, anti-aging, or wellness use, and FDA final action is pending. WADA continues to list thymosin-beta4 derivatives such as TB-500 as prohibited at all times.

Who this is for

This page is for readers asking whether TB-500 is FDA-approved, legal, banned in sport, or clinically proven for injury recovery.

It is also for editors checking whether evidence from thymosin beta-4 can be used on a TB-500 page. The answer is: only with careful caveats. Parent-molecule evidence and topical clinical trials do not establish that TB-500 injections are safe or effective.

How we chose the source base

We used FDA's official July 2026 meeting page, the TB-500 staff briefing, FDA compounding guidance, and the WADA 2026 Prohibited List as regulatory anchors. Because final FDA minutes were not yet posted on July 26, we corroborated the hearing result through independent reporting and describe it as a committee recommendation rather than final agency action.

We then reviewed PubMed-indexed thymosin beta-4 clinical literature to understand what has been studied in humans and where that evidence does not transfer cleanly to TB-500. We intentionally avoided vendor pages, clinic pages, dosing forums, and affiliate sources.

Evidence snapshot

The July committee recommendation did not create direct human exposure evidence for TB-500. FDA staff said it had not identified human exposure data for drug products containing the thymosin beta-4 fragment LKKTETQ and recommended against 503A inclusion. The committee reached a different advisory conclusion, but neither position approves a finished drug.

Human studies of full-length thymosin beta-4 include topical ophthalmic and venous-ulcer contexts, not consumer TB-500 recovery injections. Those studies are relevant to the biology of thymosin beta-4, but they do not prove safety or efficacy for TB-500 as sold online.

Safety notes

The biggest editorial risk is evidence transfer. A study of topical thymosin beta-4 solution in dry eye is not a study of injectable TB-500. A venous-ulcer trial design is not a proof of sports recovery benefit. Route, molecule, manufacturing, sterility, dose, and population all matter.

The gray-market risk is also material. Products marketed for research may be used by consumers despite lacking the controls expected for approved drug products.

Alternatives

For injury recovery, the appropriate alternative is evaluation by a qualified clinician, evidence-based rehabilitation, load management, and approved treatments when indicated. For athletes, NSF Certified for Sport supplements are a lower-risk supplement category than unapproved peptide products, but supplements still require careful review.

Publication status note

Updated July 26, 2026 after PCAC recommended TB-500 for possible 503A Bulks List inclusion. The recommendation is non-binding, TB-500 remains unapproved, and FDA final action is pending. This page remains non-promotional and provides no dosing, sourcing, injection, stacking, protocol, product, or affiliate guidance.

Official source documents

These official sources should be rechecked before publication.

Source	U R L
FDA - Safety risks and withdrawn nomination status for thymosin beta-4 fragment (LKKTETQ), also known as TB-500	https://www.fda.gov/drugs/human-drug-compounding/safety-risks-associated-certain-bulk-drug-substances-nominated-use-compounding
FDA - July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting	https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
FDA - TB-500 staff briefing document	https://www.fda.gov/media/193349/download
ABC News - Post-hearing result and non-binding status	https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915
FDA - Bulk drug substances used in compounding	https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding
WADA - 2026 Prohibited List	https://www.wada-ama.org/en/prohibited-list

Common Questions

Frequently Asked Questions

Is TB-500 FDA-approved?

No. PCAC recommended TB-500 for possible 503A Bulks List inclusion in July 2026, but that non-binding vote was not FDA approval. TB-500 remains unapproved for recovery, injury repair, bodybuilding, anti-aging, or wellness use while FDA final action is pending.

Can thymosin beta-4 studies prove TB-500 works?

No. They can provide biological context, but they cannot establish that a different fragment, route, dose, formulation, or gray-market product is safe or effective for human recovery.

Why does FDA mention no human exposure data?

FDA's statement means it lacked important human-use information for drug products containing the TB-500 fragment when assessing the nominated bulk substance. That is a safety uncertainty, not proof of safety.

Can athletes use TB-500?

Athletes should treat TB-500 as prohibited. The WADA 2026 Prohibited List names thymosin-beta4 derivatives such as TB-500 under S2.3, which is prohibited at all times.

Is TB-500 the same as full-length thymosin beta-4?

No. TB-500 typically refers to a short fragment of thymosin beta-4, often identified as LKKTETQ, while full-length thymosin beta-4 is a 43-amino-acid protein. Research suggests that evidence generated for the parent molecule in regulated topical or wound-healing formulations does not automatically transfer to a synthetic fragment delivered by injection. Pharmacology, immunogenicity profile, manufacturing quality, and clinical risk all differ between the fragment and the parent molecule.

Is TB-500 legal in the US?

Healthy Aging Atlas cannot provide legal advice, but TB-500 is not an FDA-approved drug for injury repair, recovery, anti-aging, or wellness use, and FDA identifies safety-risk concerns for the LKKTETQ fragment. Consumers should not treat online availability as proof of lawful sale, medical approval, or safe use.

Research Updates

Get healthy-aging evidence updates without the hype.

The free guide summarizes supplement evidence, quality signals, and safety questions in a practical checklist format.

Get the free guide

Primary Sources

Citations & Research

[1]Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) modelSource
[2]Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healingSource
[3]The effect of thymosin treatment of venous ulcersSource